KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Gsk (GSK) over the last 12 years, with Q4 2025 value amounting to -$453.5 million.

  • Gsk's Change in Acquisitions & Divestments rose 4291.39% to -$453.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.8 billion, marking a year-over-year decrease of 4691.36%. This contributed to the annual value of -$1.8 billion for FY2025, which is 1110.07% down from last year.
  • According to the latest figures from Q4 2025, Gsk's Change in Acquisitions & Divestments is -$453.5 million, which was up 4291.39% from -$433.0 million recorded in Q3 2025.
  • Over the past 5 years, Gsk's Change in Acquisitions & Divestments peaked at -$2.4 million during Q3 2022, and registered a low of -$794.5 million during Q4 2024.
  • Moreover, its 5-year median value for Change in Acquisitions & Divestments was -$308.6 million (2021), whereas its average is -$292.4 million.
  • In the last 5 years, Gsk's Change in Acquisitions & Divestments soared by 9916.5% in 2023 and then tumbled by 861945.42% in 2025.
  • Over the past 5 years, Gsk's Change in Acquisitions & Divestments (Quarter) stood at -$153.7 million in 2021, then plummeted by 313.69% to -$635.7 million in 2022, then fell by 12.26% to -$713.7 million in 2023, then dropped by 11.33% to -$794.5 million in 2024, then soared by 42.91% to -$453.5 million in 2025.
  • Its Change in Acquisitions & Divestments stands at -$453.5 million for Q4 2025, versus -$433.0 million for Q3 2025 and -$440.2 million for Q2 2025.